Literature DB >> 25383464

Systematic Occlusion of Shunts: Control of Early Postoperative IOP and Hypotony-related Complications Following Glaucoma Shunt Surgery.

Eamon Sharkawi1, Paul H Artes, Justyna D Oleszczuk, Cyrielle Bela, Farid Achache, Keith Barton, Ciara Bergin.   

Abstract

OBJECTIVE: Evaluation of a protocol of total intraluminal occlusion of Baerveldt shunts and its effects on early postoperative intraocular pressure (IOP) control and hypotony-related complications.
DESIGN: This was a noncomparative, prospective, and interventional study. PARTICIPANTS: Glaucoma patients were recruited to undergo Baerveldt shunt surgery. A total of 116 eyes of 112 patients were enrolled. INTERVENTION: During shunt implantation, aqueous outflow was restricted using an intraluminal occluding stent inserted through the entire tube length, with and without external ligation, to halt aqueous flow. Postoperatively, eyes underwent ligature laser suture lysis and partial or complete stent removals, at predetermined time intervals. MAIN OUTCOME MEASURE: Loss of postoperative IOP control was categorized as transient or persistent hypotony (IOP≤5 mm Hg) or hypertony (IOP>21 mm Hg). Patients were followed up for 1 year.
RESULTS: Preoperatively median IOP was 23 mm Hg (mean 26 mm Hg, SD 12 mm Hg), median number of glaucoma medications was 3.0 (mean 3.0, SD 1.2). During year 1, laser suture lysis was performed in 30 eyes (26%) and stent removal in 93 eyes (80%) (23 partial; 70 complete). There was 1 case of transient hypotony, no cases of persistent hypotony, 10 of transient hypertony, and 3 of persistent hypertony. Nine eyes had IOP≤5 mm Hg at ≥1 time points and hypotony-related complications occurred in 8 eyes (7%). At 1 year, median IOP was 12 mm Hg (mean 13 mm Hg, SD 4 mm Hg) with a median of 1.0 glaucoma medications (mean 1.1, SD 1.3). The cumulative probability of failure during the first 12 months follow-up was 6% (n=7). Overall postoperative complications occurred in 11 eyes (9%).
CONCLUSIONS: The surgical and postoperative protocol resulted in controlled, step-wise reductions of IOP with low rates of hypotony and related complications.

Entities:  

Mesh:

Year:  2016        PMID: 25383464     DOI: 10.1097/IJG.0000000000000135

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Ab interno tube ligation for refractory hypotony following non-valved glaucoma drainage device implantation.

Authors:  A Vergados; A A Mohite; Velota C T Sung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-22       Impact factor: 3.117

2.  Baerveldt tube implantation following failed deep sclerectomy versus repeat deep sclerectomy.

Authors:  C Bergin; A Petrovic; A Mermoud; E Ravinet; E Sharkawi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-31       Impact factor: 3.117

3.  Endophthalmitis associated with Glaucoma Shunt Intraluminal Stent Exposure.

Authors:  Hye Jin Kwon; Nathan M Kerr; Jonathan B Ruddle; Ghee Soon Ang
Journal:  J Curr Glaucoma Pract       Date:  2016-05-12

4.  Retinal pigment epithelium changes in pediatric patients with glaucoma drainage devices.

Authors:  Carla J Osigian; Sara Grace; Maria P Fernandez; Camila V Ventura; Susan Azar; Ta C Chang; Elizabeth Hodapp; Sander R Dubovy; Audina Berrocal
Journal:  Am J Ophthalmol Case Rep       Date:  2017-12-15

5.  Ab interno suture tube ccclusion of the Baerveldt glaucoma implant for management of postoperative hypotony: A case series.

Authors:  André S Pollmann; Amit V Mishra; Maria Gabriela Campos-Baniak; R Rishi Gupta; Brennan D Eadie
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-30

6.  Commentary: Meeting the nemesis of a non-valved glaucoma drainage device head-on.

Authors:  Vanita Pathak-Ray
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

7.  A modified technique for intraluminal stenting of glaucoma drainage devices: The guide-wire technique.

Authors:  Nicholas H Andrew; Sonia G Huang; Jamie E Craig
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.